Patent Validity and Entresto: Lessons From the Ongoing Dispute

Ms. Brougher is a patent attorney who focuses on all aspects of services related to patents in the areas of biotechnology, pharmaceuticals and medical devices, including patentability opinions, due diligence, patent drafting, domestic and foreign patent prosecution, development and management of patent portfolios, and general client counseling during all phases of a product’s lifecycle, from concept to commercialization.


 


Her patent experience covers a variety of complex and innovative inventions involving small molecule drugs, biologics, cell-based technologies, compositions, drug formulations and drug delivery systems, immunotherapeutics, medical devices, diagnostic tests, nanotechnology, and immunology, particularly vaccines and antibodies. Ms. Brougher also has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act.

Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.

Ms. Tully works at Genentech as Director and Assistant General Counsel, Neuroscience and Ophthalmology IP Lead. In her role, she works on IP policy issues with a particular focus on the biopharmaceutical industry. Prior to joining Genentech, Ms. Tully did a judicial clerkship with the Honorable Judge Raymond T. Chen at the United States Court of Appeals for the Federal Circuit. Before her clerkship, she worked as an associate at Haley Guiliano and Cooley and as a patent agent at Ropes & Gray. Ms. Tully holds a J.D. from Stanford Law School, a Ph.D. in chemistry from California Institute of Technology and a Bachelor of Arts in Biochemistry from Barnard College, Columbia University.

Ms. Wang is a first-chair trial lawyer who represents biotech, pharmaceutical, and technology companies in complex and high stakes intellectual property and commercial disputes across the country. She is a go-to resource for clients in the life sciences industry, including for “bet-the-company” patent litigation (including Hatch-Waxman and biosimilar litigation), post-grant review (PGR) and inter partes review (IPR) proceedings before the United States Patent Trial and Appeal Board (PTAB), trade secrets litigation, and contract, licensing, and other commercial disputes. Ms. Wang also routinely advises clients on the management of their US and global patent and litigation strategies, including regularly consulting with counsel before the EPO and in the UK, Germany, and other foreign jurisdictions.